中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2012年
10期
23-25
,共3页
李香彭%孟浩%许柳柳%张柳
李香彭%孟浩%許柳柳%張柳
리향팽%맹호%허류류%장류
肝素,低分子量%肺疾病,慢性阻塞性%肺源性心脏病
肝素,低分子量%肺疾病,慢性阻塞性%肺源性心髒病
간소,저분자량%폐질병,만성조새성%폐원성심장병
Heparin,low molecular weight%Pulmonary disease,chronic obstructive%Pulmonary heart disease
目的 观察低分子量肝素钙治疗慢性阻塞性肺疾病(COPD)伴发肺源性心脏病(肺心病)患者的临床疗效.方法 将2008年12月至2010年12月收治的COPD伴发肺心病的64例患者按随机数字表法分为治疗组和对照组,每组32例,对照组常规吸氧、控制感染、维持水电解质和酸碱平衡、利尿、强心等综合治疗,治疗组在对照组基础上加用低分子量肝素钙,5000 U腹部皮下注射.观察比较两组的疗效和对动脉血气分析的影响.结果 治疗组总有效率为90.6％(29/32),对照组总有效率为68.8％(22/32),两组比较差异有统计学意义(P＜0.05).治疗组治疗后动脉血二氧化碳分压(PaCO2)、动脉血氧分压(PaO2)分别为(54.64±9.63)、(74.21±11.76) mm Hg(1 mm Hg =0.133kPa),均较治疗前的(78.66±11.22)、(53.42土8.84)mm Hg显著改善,差异有统计学意义(P＜0.01)；对照组治疗后PaCO2、PaO2分别为(61.10±7.24)、( 65.07±8.21) mm Hg,均较治疗前的(79.52±12.54)、(51.35±7.31) mm Hg显著改善,差异有统计学意义(P＜0.05)；而治疗组治疗后PaCO2、PaO2的改善显著优于对照组,差异有统计学意义(P＜0.05).结论 低分子量肝素钙辅助治疗对COPD伴发肺心病患者的症状缓解和预后改善有显著的促进作用,值得临床推广应用.
目的 觀察低分子量肝素鈣治療慢性阻塞性肺疾病(COPD)伴髮肺源性心髒病(肺心病)患者的臨床療效.方法 將2008年12月至2010年12月收治的COPD伴髮肺心病的64例患者按隨機數字錶法分為治療組和對照組,每組32例,對照組常規吸氧、控製感染、維持水電解質和痠堿平衡、利尿、彊心等綜閤治療,治療組在對照組基礎上加用低分子量肝素鈣,5000 U腹部皮下註射.觀察比較兩組的療效和對動脈血氣分析的影響.結果 治療組總有效率為90.6％(29/32),對照組總有效率為68.8％(22/32),兩組比較差異有統計學意義(P＜0.05).治療組治療後動脈血二氧化碳分壓(PaCO2)、動脈血氧分壓(PaO2)分彆為(54.64±9.63)、(74.21±11.76) mm Hg(1 mm Hg =0.133kPa),均較治療前的(78.66±11.22)、(53.42土8.84)mm Hg顯著改善,差異有統計學意義(P＜0.01)；對照組治療後PaCO2、PaO2分彆為(61.10±7.24)、( 65.07±8.21) mm Hg,均較治療前的(79.52±12.54)、(51.35±7.31) mm Hg顯著改善,差異有統計學意義(P＜0.05)；而治療組治療後PaCO2、PaO2的改善顯著優于對照組,差異有統計學意義(P＜0.05).結論 低分子量肝素鈣輔助治療對COPD伴髮肺心病患者的癥狀緩解和預後改善有顯著的促進作用,值得臨床推廣應用.
목적 관찰저분자량간소개치료만성조새성폐질병(COPD)반발폐원성심장병(폐심병)환자적림상료효.방법 장2008년12월지2010년12월수치적COPD반발폐심병적64례환자안수궤수자표법분위치료조화대조조,매조32례,대조조상규흡양、공제감염、유지수전해질화산감평형、이뇨、강심등종합치료,치료조재대조조기출상가용저분자량간소개,5000 U복부피하주사.관찰비교량조적료효화대동맥혈기분석적영향.결과 치료조총유효솔위90.6％(29/32),대조조총유효솔위68.8％(22/32),량조비교차이유통계학의의(P＜0.05).치료조치료후동맥혈이양화탄분압(PaCO2)、동맥혈양분압(PaO2)분별위(54.64±9.63)、(74.21±11.76) mm Hg(1 mm Hg =0.133kPa),균교치료전적(78.66±11.22)、(53.42토8.84)mm Hg현저개선,차이유통계학의의(P＜0.01)；대조조치료후PaCO2、PaO2분별위(61.10±7.24)、( 65.07±8.21) mm Hg,균교치료전적(79.52±12.54)、(51.35±7.31) mm Hg현저개선,차이유통계학의의(P＜0.05)；이치료조치료후PaCO2、PaO2적개선현저우우대조조,차이유통계학의의(P＜0.05).결론 저분자량간소개보조치료대COPD반발폐심병환자적증상완해화예후개선유현저적촉진작용,치득림상추엄응용.
Objective To observe the clinical effect of low molecular weight heparin calcium in the treatment of chronic obstructive pulmonary disease combined with pulmonary heart disease.Methods A total of 64 patients with chronic obstructive pulmonary disease combined with pulmonary heart disease from December 2008 to December 2010 were enrolled in this study and divided into treatment group and control group by random digits table with 32 cases each.The control group was given routine treatment and the treatment group was given low molecular weight heparin calcium for 7 days at the basis of routine treatment.Results The total effective rate in treatment group [ 90.6％ (29/32) ] was significantly higher than that in control group [ 68.8％ (22/32) ] (P ＜ 0.05 ).In treatment group,the levels of arterial carbon dioxide tension (PaCO2) and arterial oxygen tension (PaO2) after treatment [(54.64±9.63),(74.21 ± 11.76) mm Hg (1 mm Hg =0.133 kPa)] were significantly decreased compared with before treatment [(78.66 ± 11.22),(53.42 ± 8.84 ) mm Hg ] (P ＜ 0.01 ).In control group,the levels of PaCO2 and PaO2 after treatment [ (61.10 ±7.24),(65.07 ± 8.21 ) mm Hg] were significantly decreased compared with before treatment [ (79.52 ± 12.54),(51.35 ± 7.31 ) mm Hg ] (P ＜ 0.05 ).After treatment the levels of PaCO2 and PaO2 in treatment group were better than those in control group (P ＜ 0.05).Conclusions The low molecular weight heparin calcium in treatment of chronic obstructive pulmonary disease combined with pulmonary heart disease can effectively improve the clinical manifestation.It is worth the clinical promoted application.
